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WARNINGS AND PRECAUTIONS Hepatic Toxicity
• Measure serum transaminase levels and bilirubin at the initiation of voriconazole therapy and monitor at least weekly for the first month of treatment. Monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are noted. If liver function tests become markedly elevated compared to baseline, voriconazole should be discontinued unless the medical judgment of the benefit-risk of the treatment for the patient justifies continued use.
Arrhythmias and QT Prolongation
• Voriconazole should be administered with caution to patients with potentially proarrhythmic conditions, such as patients with congenital or acquired QT-prolongation; cardiomyopathy, in particular when heart failure is present; sinus bradycardia; those with existing symptomatic arrhythmias; or concomitant medicinal product that is known to prolong QT interval. • Rigorous attempts to correct potassium, magnesium, and calcium should be made before starting and during voriconazole therapy.
Dermatological Reactions
• Voriconazole has been associated with photosensitivity skin reaction. Measures such as protective clothing and sunscreen with high sun protection factor (SPF) should be recommended. • The frequency of phototoxicity reactions is higher in the pediatric population. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm283035.htm a Practitioners are encouraged to check the US Food and Drug Administration's MedWatch Web site (http://www.fda.gov/medwatch/safety.htm) for updated information.
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